YTHDC1 is downregulated by the YY1/HDAC2 complex and controls the sensitivity of ccRCC to sunitinib by targeting the ANXA1-MAPK pathway

BACKGROUND: Tyrosine kinase inhibitors (TKIs) such as sunitinib are multitarget antiangiogenic agents in clear cell renal cell carcinoma (ccRCC). They are widely used in the treatment of advanced/metastatic renal cancer. However, resistance to TKIs is common in the clinic, particularly after long-te...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Wei, Ye, Kun, Li, Xurui, Liu, Xinlin, Peng, Mou, Chen, Fang, Xiong, Wei, Wang, Yinhuai, Zhu, Liang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9382764/
https://www.ncbi.nlm.nih.gov/pubmed/35974388
http://dx.doi.org/10.1186/s13046-022-02460-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9382764/
https://www.ncbi.nlm.nih.gov/pubmed/35974388
http://dx.doi.org/10.1186/s13046-022-02460-9

Ejemplares similares